Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million
Dear Ocumetics Investors,
I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first tranche of our secured convertible debenture financing with an aggregate face value of $3,000,000. This debenture, issued with a 6% original issue discount, has provided us with net proceeds of $2,820,000, less associated lender expenses. Our total offering aims to raise up to $4,000,000, and we are confident that we will close the remaining amount in one or more subsequent tranches within the next 30 days.
Moving Towards First-In-Human Trials
This substantial financial milestone allows us to immediately advance our ground-breaking technology to the next critical phase: our first-in-human trials. These trials, scheduled to take place later this year in the Dominican Republic, represent a pivotal step in demonstrating the potential of our innovative eye care solutions to improve vision and quality of life for countless individuals.
Our team has been diligently preparing for this moment, and we are ready to move forward with the necessary preparations and regulatory approvals to ensure the success of these trials. This funding will enable us to finalize these preparations and take the essential steps to bring our technology to the forefront of medical science.
The Path Ahead
The first-in-human trials are not just a technical requirement; they are a testament to our commitment to innovation and our dedication to providing life-changing solutions. These trials will provide us with invaluable data and insights, helping us refine our technology and move closer to our goal of commercialization.
In the coming weeks, I will share more detailed information about the specific activities and milestones we aim to achieve through these trials. Our team is incredibly motivated and focused, and we believe that these trials will showcase the efficacy and safety of our technology, setting the stage for broader clinical applications and market entry.
Strengthening Our Financial Position
The secured convertible debenture financing has been strategically structured to ensure that we have the necessary capital to drive our projects forward without compromising our financial stability. By securing this financing, we are reinforcing our commitment to responsible financial management while aggressively pursuing our research and development goals.
This funding also reflects the confidence and trust that our investors have in Ocumetics and our vision for the future. We are grateful for your continued support and belief in our mission. Your investment is instrumental in helping us achieve our objectives and make a tangible difference in the field of ophthalmology.
This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed. I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief
Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens. What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of
Ocumetics Director and CEO, Dean Burns, covers key details of our upcoming first-in-human study and recently opened private placement financing. Topics will include: Final steps leading up to the first-in-human study Details on the now-open private placement investment opportunity Live Q&A session with Dean Burns Thanks to everyone who joined us for the Webinar. It
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including: First-in-human study timing Remaining steps to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
